Novel Therapeutic Options for Solitary Fibrous Tumor: Antiangiogenic Therapy and Beyond
- de Bernardi, Axel
- Dufresne, Armelle
- Mishellany, Florence
- Blay, Jean-Yves
- Ray-Coquard, Isabelle
- Brahmi, Mehdi
DOIAbstract
International audienceSFT is an ultrarare mesenchymal ubiquitous tumor, with an incidence rate <1 case/million people/year. The fifth WHO classification published in April 2020 subdivided SFT into three categories: benign (locally aggressive), NOS (rarely metastasizing), and malignant. Recurrence can occur in up to 10–40% of localized SFTs, and several risk stratification models have been proposed to predict the individual risk of metastatic relapse. The Demicco model is the most widely used and is based on age at presentation, tumor size, and mitotic count. Total en bloc resection is the standard treatment of patients with a localized SFT; in case of advanced disease, the clinical efficacy of conventional chemotherapy remains poor. In this...
Add to ORKG
